FH-006
/ Jiangsu Hengrui Pharma, Shanghai Fuhong Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
September 05, 2026
A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=150 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Oncology • Solid Tumor
August 28, 2026
FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy.
(clinicaltrials.gov)
- P3 | N=480 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.
New P3 trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma
November 22, 2025
A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
(clinicaltrials.gov)
- P2 | N=200 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.
New P2 trial • Lung Cancer • Oncology • Solid Tumor
August 23, 2025
A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=150 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.
New P1/2 trial • Solid Tumor
January 28, 2025
Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=200 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Oncology • Solid Tumor
1 to 5
Of
5
Go to page
1